Nobel laureate’s CRISPR biotech shuts down as funding runs out

Caribou Biosciences was one of the early companies to embrace CRISPR gene-editing technology. Now, the biotech is being forced to halt development of its cancer therapies, despite having a candidate ready for phase III.